IMV: to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022 – Form 6-K







IMV Inc. to Announce Second Quarter 2022 Results and Host Conference Call and Webcast on August 11, 2022

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.August 4, 2022 — IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV“or the”Company“) a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers, announced today that it will hold a conference call and webcast on Thursday, August 11, 2022 at 8:00 p.m. ET to discuss the company’s second quarter 2022 financial and operating results.

Financial analysts are invited to join the conference call by registering at this link before the call to receive their individual login information.

Other interested parties will be able to access the live audio webcast by registering on the IMV website: https://ir.imv-inc.com/events-and-presentations. The webcast will be recorded and will then be available on the IMV website for 30 days after the call.

About IMV

IMV Inc. is a clinical-stage immuno-oncology company developing a portfolio of therapies based on the company’s immune education platform, DPX™. Through a differentiated mechanism of action, the DPX platform provides instructions to the immune system to generate a specific, robust and persistent immune response. IMV’s lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides from survivin, a well-known cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immune enhancer and a universal CD4 T cell helper peptide. These elements promote maturation of antigen-presenting cells as well as robust activation of CD8 T-cell effector and memory function. MVP-S treatment was well tolerated and demonstrated definite clinical benefit in multiple cancer indications as well as activation of a targeted and sustained survivin-specific anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematological and solid cancers, including diffuse large B-cell lymphoma (DLBCL) as well as ovarian, bladder and breast cancers. IMV is also developing a second immunotherapy based on the DPX immune delivery platform, DPX-SurMAGE. This dual-target immunotherapy combines antigenic peptides for survivin and cancer proteins MAGE-A9 to simultaneously trigger immune responses to these two distinct cancer antigens. A Phase 1 clinical trial in bladder cancer, using MVP-S or DPX-SurMAGE, was initiated in early 2022. For more information, visit www.imv-inc.com and connect with us on Twitter and LinkedIn.

IMV forward-looking statements

This press release contains forward-looking information under applicable securities laws. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use words such as “will”, “may”, “potential”, “believe”, “expect”, “continue”, “anticipate” and other similar terms.

Forward-looking statements are based on management’s estimates and opinions as of the date the statements are made. In this press release, such forward-looking statements include, but are not limited to, statements regarding the potential impact of the VITALIZE study and the expected date of availability of data from this study, the Company’s ability to advance its development strategy, as well as the outlook, for its lead immunotherapy and other immunotherapy candidate pipelines. However, they should not be taken as a representation that any of the plans will be realized. Actual results may differ materially from those indicated in this press release due to risks affecting the Company, including access to capital, the successful design and completion of clinical trials and the timely receipt of all approvals. regulations to begin, then continue, clinical studies. and testing and receipt of all regulatory approvals to market its products. IMV Inc. assumes no responsibility to update any forward-looking statements in this press release, except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and such risks and uncertainties include, but are not limited to, those relating to the Company’s expected timing associated with its cash flow; the Company’s priorities with MVP-S and its DPX delivery platform, the potential of its delivery platform and the expected timing of enrollment and results of its clinical trial programs and studies, as well as d other risks detailed from time to time in our quarterly filings and our current annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current Annual Information Form, as well as its audited annual consolidated financial statements which are available on SEDAR at www. .sedar.com and on EDGAR at www.sec.gov/edgar.

Investor Relations

Irina Koffler, Managing Director, LifeSci Advisors
Telephone: (646) 970-4681
M: (917) 734-7387
Email: [email protected]

Media

Delphine Davan, Senior Director, Communications and Investor Relations, IMV Inc.
O: (902) 492.1819 ext: 1049
Email: [email protected]

Madeline Joanis, Senior Account Manager, LifeSci Communications
M: (603) 479 5267
Email: [email protected]

Disclaimer

IMV inc. published this content on August 05, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on August 05, 2022 16:05:02 UTC.

Public now 2022

2022 sales 1.97 million
1.52M
1.52M
Net income 2022 -52.7M
-40.7M
-40.7M
Net debt 2022

PER 2022 ratio -1.04x
2022 return
Capitalization 53.5 million
41.4 million
41.4 million
capi. / Sales 2022 27.2x
capi. / Sales 2023 19.5x
# of employees 97
Floating 99.4%


Duration :

Period :




IMV Inc. Technical Analysis Chart |  MarketScreener

Trends in technical analysis IMV INC.

Short term Middle term Long term
Tendencies Bearish Bearish Bearish



Evolution of the income statement

Sale

To buy

Medium consensus TO BUY
Number of analysts 6
Last closing price $0.65
Average target price $7.27
Average Spread / Target 1,018%


Michael P. Boser